Phaseline

Companies › OriCell Therapeutics

OriCell Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OriCAR-017
GPRC5D-directed chimeric antigen receptor (CAR) modified T cells
GPRC5DPhase 1Relapsed and/or Refractory Multiple Myeloma; Neoplasms, Plasma CellNov 2026
Ori-C101
GPC3-directed CAR-T cell therapy
GPRC3Phase 1Hepatocellular CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06182696OriCAR-017Phase 1Relapsed and/or Refractory Multiple MyelomaOncologyNov 2026
NCT06271252OriCAR-017Phase 1Neoplasms, Plasma CellOncologyDec 2026
NCT05652920Ori-C101Phase 1Hepatocellular CarcinomaOncologyDec 2026

Targets

GPRC3 (1) GPRC5D (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Guangzhou FineImmune Biotechnology Regeneron Pharmaceuticals Bristol-Myers Squibb Nanjing IASO Biotechnology O&D BioTech Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Bayer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.